Symbols / GRI Stock $2.36 -2.48% GRI Bio, Inc.

Healthcare • Biotechnology • United States • NCM
GRI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. W. Marc Hertz Ph.D.
Exch · Country NCM · United States
Market Cap 3.41M
Enterprise Value -4.75M
Income -11.96M
Sales —
FCF (ttm) -5.47M
Book/sh 12.07
Cash/sh 5.70
Employees 3
Insider 10d —
IPO Feb 10, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.29
PEG —
P/S —
P/B 0.20
P/C —
EV/EBITDA 0.40
EV/Sales —
Quick Ratio 3.11
Current Ratio 3.25
Debt/Eq 1.18
LT Debt/Eq —
EPS (ttm) -121.80
EPS next Y -8.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-01-30
Earnings (prior) 2026-01-30
ROA -103.93%
ROE -238.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.45M
Shs Float 1.45M
Insider Own 0.57%
Instit Own 0.15%
Short Float 9.30%
Short Ratio 0.88
Short Interest 134.38K
52W High 80.36
vs 52W High -97.06%
52W Low 2.10
vs 52W Low 12.38%
Beta -1.24
Impl. Vol. —
Rel Volume 0.13
Avg Volume 158.49K
Volume 21.14K
Target (mean) $160.00
Tgt Median $160.00
Tgt Low $40.00
Tgt High $280.00
# Analysts 2
Recom None
Prev Close $2.42
Price $2.36
Change -2.48%
About

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$160.00
Mean price target
2. Current target
$2.36
Latest analyst target
3. DCF / Fair value
$-68.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.36
Low
$40.00
High
$280.00
Mean
$160.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 main Ascendiant Capital Buy → Buy $40
2025-12-08 main Ascendiant Capital Buy → Buy $36
2025-09-22 main Ascendiant Capital Buy → Buy $35
2025-06-11 reit HC Wainwright & Co. Buy → Buy $10
2025-05-27 main Ascendiant Capital Buy → Buy $34
2025-04-14 reit HC Wainwright & Co. Buy → Buy $10
2024-12-09 init HC Wainwright & Co. — → Buy $10
2024-12-05 main Ascendiant Capital Buy → Buy $13
News
RSS: Latest GRI news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
11.98
+45.44%
8.23
-27.68%
11.39
+408.58%
2.24
Research And Development
6.82
+80.97%
3.77
+16.58%
3.23
+1235.54%
0.24
Selling General And Administration
5.16
+15.47%
4.47
-45.22%
8.15
+308.36%
2.00
General And Administrative Expense
5.16
+15.47%
4.47
-45.22%
8.15
+308.36%
2.00
Other Gand A
5.16
+15.47%
4.47
-45.22%
8.15
+308.36%
2.00
Total Expenses
11.98
+45.44%
8.23
-27.68%
11.39
+408.58%
2.24
Operating Income
-11.98
-45.44%
-8.23
+27.68%
-11.39
-408.58%
-2.24
Total Operating Income As Reported
-11.98
-45.44%
-8.23
+27.68%
-11.39
-408.58%
-2.24
EBITDA
-11.97
-45.46%
-8.23
+24.84%
-10.95
-327.61%
-2.56
Normalized EBITDA
-11.97
-45.46%
-8.23
+24.84%
-10.95
-389.76%
-2.24
Reconciled Depreciation
0.00
+0.00%
0.00
+0.00%
0.00
+33.33%
0.00
EBIT
-11.98
-45.44%
-8.23
+24.83%
-10.96
-327.26%
-2.56
Total Unusual Items
—
—
0.18
+156.00%
-0.33
Total Unusual Items Excluding Goodwill
—
—
0.18
+156.00%
-0.33
Special Income Charges
—
—
0.00
+100.00%
-0.33
Other Special Charges
—
—
—
0.33
Net Income
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Pretax Income
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Net Non Operating Interest Income Expense
0.02
-16.00%
0.03
+101.20%
-2.08
-218.84%
-0.65
Interest Expense Non Operating
—
—
2.08
+218.84%
0.65
Net Interest Income
0.02
-16.00%
0.03
+101.20%
-2.08
-218.84%
-0.65
Interest Expense
—
—
2.08
+218.84%
0.65
Interest Income Non Operating
0.02
-16.00%
0.03
—
—
Interest Income
0.02
-16.00%
0.03
—
—
Other Income Expense
—
0.00
-99.31%
0.43
+232.92%
-0.33
Other Non Operating Income Expenses
—
0.00
-99.31%
0.43
—
Gain On Sale Of Security
—
—
0.18
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Net Income From Continuing Operation Net Minority Interest
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Net Income From Continuing And Discontinued Operation
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Net Income Continuous Operations
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Normalized Income
-11.96
-45.68%
-8.21
+37.05%
-13.04
-350.80%
-2.89
Net Income Common Stockholders
-11.96
-18.17%
-10.12
+22.39%
-13.04
-305.25%
-3.22
Otherunder Preferred Stock Dividend
0.00
-100.00%
1.91
—
—
Diluted EPS
-121.80
+92.12%
-1,545.55
+98.77%
-125,355.77
-164.97%
-47,308.82
Basic EPS
-121.80
+92.12%
-1,545.55
+98.77%
-125,355.77
-164.97%
-47,308.82
Basic Average Shares
0.10
+1399.56%
0.01
+6194.23%
0.00
+52.94%
0.00
Diluted Average Shares
0.10
+1399.56%
0.01
+6194.23%
0.00
+52.94%
0.00
Diluted NI Availto Com Stockholders
-11.96
-18.17%
-10.12
+22.39%
-13.04
-305.25%
-3.22
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.67
+51.00%
5.74
+94.15%
2.96
+671.80%
0.38
Current Assets
8.59
+53.02%
5.62
+91.38%
2.93
+840.38%
0.31
Cash Cash Equivalents And Short Term Investments
8.23
+63.66%
5.03
+178.10%
1.81
+19988.89%
0.01
Cash And Cash Equivalents
8.23
+63.66%
5.03
+178.10%
1.81
+19988.89%
0.01
Cash Financial
8.23
+63.66%
5.03
+178.10%
1.81
+19988.89%
0.01
Other Current Assets
0.36
-38.16%
0.59
-47.87%
1.13
+271.62%
0.30
Total Non Current Assets
0.07
-40.32%
0.12
+463.64%
0.02
-69.01%
0.07
Net PPE
0.07
-40.32%
0.12
+463.64%
0.02
-69.01%
0.07
Gross PPE
0.11
-29.87%
0.15
+220.83%
0.05
-48.39%
0.09
Accumulated Depreciation
-0.03
-13.33%
-0.03
-15.38%
-0.03
-18.18%
-0.02
Machinery Furniture Equipment
0.04
+8.82%
0.03
+0.00%
0.03
+30.77%
0.03
Other Properties
0.07
-40.83%
0.12
+757.14%
0.01
-79.10%
0.07
Non Current Prepaid Assets
—
—
—
0.00
Total Liabilities Net Minority Interest
2.66
+55.71%
1.71
-36.71%
2.70
+34.31%
2.01
Current Liabilities
2.64
+61.55%
1.64
-39.34%
2.70
+35.26%
1.99
Payables And Accrued Expenses
2.59
+62.91%
1.59
-40.75%
2.68
+101.50%
1.33
Payables
1.84
+104.79%
0.90
-36.38%
1.41
+8.96%
1.29
Accounts Payable
1.84
+104.79%
0.90
-36.38%
1.41
+8.96%
1.29
Current Accrued Expenses
0.75
+8.54%
0.69
-45.59%
1.27
+3427.78%
0.04
Pensionand Other Post Retirement Benefit Plans Current
—
—
—
0.03
Current Debt And Capital Lease Obligation
0.06
+16.67%
0.05
+242.86%
0.01
-97.88%
0.66
Current Debt
—
—
—
0.60
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
0.06
+16.67%
0.05
+242.86%
0.01
-75.44%
0.06
Current Deferred Liabilities
—
—
0.00
-100.00%
0.01
Other Current Liabilities
—
—
0.00
—
Total Non Current Liabilities Net Minority Interest
0.01
-78.87%
0.07
0.00
-100.00%
0.01
Long Term Debt And Capital Lease Obligation
0.01
-78.87%
0.07
0.00
-100.00%
0.01
Long Term Capital Lease Obligation
0.01
-78.87%
0.07
0.00
-100.00%
0.01
Stockholders Equity
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Common Stock Equity
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
0.50
+2551.95%
0.02
+17945.19%
0.00
+52.94%
0.00
Ordinary Shares Number
0.50
+2551.95%
0.02
+17945.19%
0.00
+52.94%
0.00
Additional Paid In Capital
57.70
+31.83%
43.77
+37.68%
31.79
+88.44%
16.87
Retained Earnings
-51.70
-30.09%
-39.74
-26.03%
-31.53
-70.49%
-18.50
Total Equity Gross Minority Interest
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Total Capitalization
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Working Capital
5.95
+49.51%
3.98
+1578.90%
0.24
+114.09%
-1.68
Invested Capital
6.01
+49.01%
4.03
+1456.76%
0.26
+125.32%
-1.02
Total Debt
0.07
-40.34%
0.12
+750.00%
0.01
-97.92%
0.67
Net Debt
—
—
—
0.59
Capital Lease Obligations
0.07
-40.34%
0.12
+750.00%
0.01
-80.28%
0.07
Net Tangible Assets
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Tangible Book Value
6.01
+49.01%
4.03
+1456.76%
0.26
+115.94%
-1.62
Current Notes Payable
—
—
0.00
-100.00%
0.60
Interest Payable
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.19
-18.29%
-8.61
+4.22%
-8.99
-728.57%
-1.08
Cash Flow From Continuing Operating Activities
-10.19
-18.29%
-8.61
+4.22%
-8.99
-728.57%
-1.08
Net Income From Continuing Operations
-11.96
-45.68%
-8.21
+37.05%
-13.04
-305.25%
-3.22
Depreciation Amortization Depletion
0.00
+0.00%
0.00
+0.00%
0.00
+33.33%
0.00
Depreciation
0.00
+0.00%
0.00
+0.00%
0.00
+33.33%
0.00
Depreciation And Amortization
0.00
+0.00%
0.00
+0.00%
0.00
+33.33%
0.00
Other Non Cash Items
0.05
+145.71%
-0.10
-104.87%
2.16
+894.01%
0.22
Stock Based Compensation
0.79
+435.81%
0.15
-61.86%
0.39
+1452.00%
0.03
Asset Impairment Charge
—
—
0.05
+12.77%
0.05
Operating Gains Losses
—
-0.00
+98.35%
-0.18
-156.00%
0.33
Gain Loss On Investment Securities
—
-0.00
+98.35%
-0.18
—
Change In Working Capital
0.93
+306.47%
-0.45
-126.67%
1.68
+10.89%
1.51
Change In Prepaid Assets
0.25
-19.81%
0.31
+157.22%
-0.55
-1462.86%
-0.04
Change In Payables And Accrued Expense
0.72
+183.37%
-0.87
-137.92%
2.28
+43.38%
1.59
Change In Accrued Expense
0.06
+112.32%
-0.48
-483.20%
0.12
-82.04%
0.70
Change In Payable
0.66
+271.32%
-0.39
-117.92%
2.16
+140.69%
0.90
Change In Account Payable
0.66
+271.32%
-0.39
-117.92%
2.16
+140.69%
0.90
Change In Other Current Liabilities
-0.05
-145.71%
0.10
+284.21%
-0.06
-32.56%
-0.04
Investing Cash Flow
-0.00
0.00
+100.00%
-0.01
-166.67%
-0.00
Cash Flow From Continuing Investing Activities
-0.00
0.00
+100.00%
-0.01
-166.67%
-0.00
Net PPE Purchase And Sale
-0.00
0.00
+100.00%
-0.01
-166.67%
-0.00
Purchase Of PPE
-0.00
0.00
+100.00%
-0.01
-166.67%
-0.00
Capital Expenditure
-0.00
—
-0.01
-166.67%
-0.00
Financing Cash Flow
13.39
+13.18%
11.83
+9.58%
10.80
+972.19%
1.01
Cash Flow From Continuing Financing Activities
13.39
+13.18%
11.83
+9.58%
10.80
+972.19%
1.01
Net Issuance Payments Of Debt
—
0.00
-100.00%
1.25
+0.00%
1.25
Issuance Of Debt
—
0.00
-100.00%
1.25
-16.67%
1.50
Repayment Of Debt
—
—
0.00
+100.00%
-0.25
Long Term Debt Issuance
—
—
—
1.38
Long Term Debt Payments
—
—
—
-0.12
Net Long Term Debt Issuance
—
—
—
1.25
Short Term Debt Issuance
—
0.00
-100.00%
1.25
-16.67%
1.50
Short Term Debt Payments
—
—
0.00
+100.00%
-0.25
Net Short Term Debt Issuance
—
0.00
-100.00%
1.25
+0.00%
1.25
Net Common Stock Issuance
15.56
+18.75%
13.10
+6.96%
12.25
+9979.03%
-0.12
Common Stock Payments
-0.00
+0.00%
-0.00
0.00
+100.00%
-0.12
Repurchase Of Capital Stock
-0.00
+0.00%
-0.00
0.00
+100.00%
-0.12
Proceeds From Stock Option Exercised
0.00
-100.00%
0.76
+6250.00%
0.01
0.00
Net Other Financing Charges
-2.17
-6.69%
-2.03
+25.12%
-2.71
-2181.51%
-0.12
Changes In Cash
3.20
-0.59%
3.22
+78.99%
1.80
+2320.99%
-0.08
Beginning Cash Position
5.03
+178.10%
1.81
+19988.89%
0.01
-90.00%
0.09
End Cash Position
8.23
+63.66%
5.03
+178.10%
1.81
+19988.89%
0.01
Free Cash Flow
-10.19
-18.33%
-8.61
+4.30%
-9.00
-727.02%
-1.09
Interest Paid Supplemental Data
—
—
0.00
-100.00%
0.03
Common Stock Issuance
15.56
+18.75%
13.10
+6.96%
12.25
0.00
Issuance Of Capital Stock
15.56
+18.75%
13.10
+6.96%
12.25
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category